The Total number of records shown on this page is 100. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_133	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁶ MOI	In-vitro result1% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_134	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 1 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁶ MOI	In-vitro result1% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_135	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 2 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁶ MOI	In-vitro result25% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_136	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 5 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁶ MOI	In-vitro result16% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_137	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁵ MOI	In-vitro result1% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_138	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 1 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁵ MOI	In-vitro result5% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_139	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 2 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁵ MOI	In-vitro result20% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_140	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 5 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁵ MOI	In-vitro result32% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_141	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁴ MOI	In-vitro result3% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_142	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 1 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁴ MOI	In-vitro result10% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_143	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 2 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁴ MOI	In-vitro result30% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_144	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 5 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁴ MOI	In-vitro result32% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_145	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻³ MOI	In-vitro result15% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_146	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 1 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻³ MOI	In-vitro result10% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_147	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 2 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻³ MOI	In-vitro result33% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_148	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 5 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻³ MOI	In-vitro result51% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_149	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻² MOI	In-vitro result20% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_150	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 1 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻² MOI	In-vitro result26% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_151	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 2 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻² MOI	In-vitro result49% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_152	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 5 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻² MOI	In-vitro result98% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_153	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻¹ MOI	In-vitro result25% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_154	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 1 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻¹ MOI	In-vitro result40% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_155	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 2 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻¹ MOI	In-vitro result54% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_156	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 5 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻¹ MOI	In-vitro result58% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_157	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration1 MOI	In-vitro result28% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_158	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 1 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration1 MOI	In-vitro result45% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_159	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 2 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration1 MOI	In-vitro result50% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_160	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 5 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration1 MOI	In-vitro result58% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_161	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3 MOI	In-vitro result30% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_162	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 1 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3 MOI	In-vitro result40% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_163	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 2 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3 MOI	In-vitro result50% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_164	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 5 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3 MOI	In-vitro result70% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_165	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁷ MOI	In-vitro result5% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_166	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 1 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁷ MOI	In-vitro result10% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_167	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 3 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁷ MOI	In-vitro result10% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_168	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁶ MOI	In-vitro result9% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_169	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 1 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁶ MOI	In-vitro result6% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_170	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 3 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁶ MOI	In-vitro result3% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_171	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁵ MOI	In-vitro result15% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_172	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 1 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁵ MOI	In-vitro result10% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_173	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 3 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁵ MOI	In-vitro result5% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_174	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁴ MOI	In-vitro result40% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_175	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 1 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁴ MOI	In-vitro result44% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_176	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 3 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁴ MOI	In-vitro result43% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_177	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻³ MOI	In-vitro result49% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_178	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 1 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻³ MOI	In-vitro result46% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_179	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 3 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻³ MOI	In-vitro result42% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_180	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻² MOI	In-vitro result51% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_181	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 1 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻² MOI	In-vitro result52% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_182	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 3 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻² MOI	In-vitro result52% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_183	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻¹ MOI	In-vitro result51% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_184	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 1 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻¹ MOI	In-vitro result52% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_185	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 3 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻¹ MOI	In-vitro result52% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_186	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration1 MOI	In-vitro result51% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_187	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 1 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration1 MOI	In-vitro result52% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_188	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 3 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration1 MOI	In-vitro result52% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_189	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3 MOI	In-vitro result54% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_190	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 1 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3 MOI	In-vitro result52% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_191	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 3 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3 MOI	In-vitro result60% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_192	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismFemale athymic nu/nu mice injected intracranially with GBM30 cells 1.0E+5 cells	In-vivo virus concentration5.0E+5 PFU (on 5 day) in total 8 mice	In-vivo toxicityNA	In-vivo result40% mice survived on 28th day	Mode of deliveryIntratumorally	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_193	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubastatin A (TA) at a dose of 1.3 mg per kg body weight (4, 5, 6, 7 and 8 days after tumor implantation)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismFemale athymic nu/nu mice injected intracranially with GBM30 cells 1.0E+5 cells	In-vivo virus concentration5.0E+5 PFU (on 5 day) in total 8 mice	In-vivo toxicityNA	In-vivo result80% mice survived on 28th day	Mode of deliveryIntratumorally	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_360	Virus nameHerpes simplex virus	Virus strainSeprehvir (HSV1716)	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationΔγ134.5 attenuated virus mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC or from the Pediatric Preclinical Testing Program (PPTP)	Origin of cell lineHuman neuroblastoma cell line	Cell lineCHLA-20	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTS cell survival assay	In-vitro virus concentration0.0001 MOI	In-vitro result100% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26583803
IDOV_361	Virus nameHerpes simplex virus	Virus strainSeprehvir (HSV1716)	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationΔγ134.5 attenuated virus mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC or from the Pediatric Preclinical Testing Program (PPTP)	Origin of cell lineHuman neuroblastoma cell line	Cell lineCHP-134	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTS cell survival assay	In-vitro virus concentration0.0001 MOI	In-vitro result100% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26583803
IDOV_362	Virus nameHerpes simplex virus	Virus strainSeprehvir (HSV1716)	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationΔγ134.5 attenuated virus mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC or from the Pediatric Preclinical Testing Program (PPTP)	Origin of cell lineHuman neuroblastoma cell line	Cell lineSK-N-AS	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTS cell survival assay	In-vitro virus concentration0.0001 MOI	In-vitro result100% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26583803
IDOV_363	Virus nameHerpes simplex virus	Virus strainSeprehvir (HSV1716)	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationΔγ134.5 attenuated virus mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC or from the Pediatric Preclinical Testing Program (PPTP)	Origin of cell lineHuman neuroblastoma cell line	Cell lineSK-N-BE(2)	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTS cell survival assay	In-vitro virus concentration0.0001 MOI	In-vitro result100% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26583803
IDOV_364	Virus nameHerpes simplex virus	Virus strainSeprehvir (HSV1716)	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationΔγ134.5 attenuated virus mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC or from the Pediatric Preclinical Testing Program (PPTP)	Origin of cell lineHuman neuroblastoma cell line	Cell lineCHLA-20	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTS cell survival assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26583803
IDOV_365	Virus nameHerpes simplex virus	Virus strainSeprehvir (HSV1716)	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationΔγ134.5 attenuated virus mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC or from the Pediatric Preclinical Testing Program (PPTP)	Origin of cell lineHuman neuroblastoma cell line	Cell lineCHP-134	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTS cell survival assay	In-vitro virus concentration0.01 MOI	In-vitro result18% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26583803
IDOV_366	Virus nameHerpes simplex virus	Virus strainSeprehvir (HSV1716)	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationΔγ134.5 attenuated virus mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC or from the Pediatric Preclinical Testing Program (PPTP)	Origin of cell lineHuman neuroblastoma cell line	Cell lineSK-N-AS	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTS cell survival assay	In-vitro virus concentration0.01 MOI	In-vitro result76% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26583803
IDOV_367	Virus nameHerpes simplex virus	Virus strainSeprehvir (HSV1716)	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationΔγ134.5 attenuated virus mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC or from the Pediatric Preclinical Testing Program (PPTP)	Origin of cell lineHuman neuroblastoma cell line	Cell lineSK-N-BE(2)	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTS cell survival assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26583803
IDOV_368	Virus nameHerpes simplex virus	Virus strainSeprehvir (HSV1716)	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationΔγ134.5 attenuated virus mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC or from the Pediatric Preclinical Testing Program (PPTP)	Origin of cell lineHuman neuroblastoma cell line	Cell lineCHLA-20	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTS cell survival assay	In-vitro virus concentration0.1 MOI	In-vitro result98% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26583803
IDOV_369	Virus nameHerpes simplex virus	Virus strainSeprehvir (HSV1716)	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationΔγ134.5 attenuated virus mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC or from the Pediatric Preclinical Testing Program (PPTP)	Origin of cell lineHuman neuroblastoma cell line	Cell lineCHP-134	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTS cell survival assay	In-vitro virus concentration0.1 MOI	In-vitro result1% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26583803
IDOV_370	Virus nameHerpes simplex virus	Virus strainSeprehvir (HSV1716)	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationΔγ134.5 attenuated virus mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC or from the Pediatric Preclinical Testing Program (PPTP)	Origin of cell lineHuman neuroblastoma cell line	Cell lineSK-N-AS	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTS cell survival assay	In-vitro virus concentration0.1 MOI	In-vitro result26% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26583803
IDOV_371	Virus nameHerpes simplex virus	Virus strainSeprehvir (HSV1716)	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationΔγ134.5 attenuated virus mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC or from the Pediatric Preclinical Testing Program (PPTP)	Origin of cell lineHuman neuroblastoma cell line	Cell lineSK-N-BE(2)	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTS cell survival assay	In-vitro virus concentration0.1 MOI	In-vitro result58% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26583803
IDOV_372	Virus nameHerpes simplex virus	Virus strainSeprehvir (HSV1716)	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationΔγ134.5 attenuated virus mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC or from the Pediatric Preclinical Testing Program (PPTP)	Origin of cell lineHuman neuroblastoma cell line	Cell lineCHLA-20	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTS cell survival assay	In-vitro virus concentration1 MOI	In-vitro result72% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26583803
IDOV_373	Virus nameHerpes simplex virus	Virus strainSeprehvir (HSV1716)	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationΔγ134.5 attenuated virus mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC or from the Pediatric Preclinical Testing Program (PPTP)	Origin of cell lineHuman neuroblastoma cell line	Cell lineCHP-134	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTS cell survival assay	In-vitro virus concentration1 MOI	In-vitro result1% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26583803
IDOV_374	Virus nameHerpes simplex virus	Virus strainSeprehvir (HSV1716)	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationΔγ134.5 attenuated virus mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC or from the Pediatric Preclinical Testing Program (PPTP)	Origin of cell lineHuman neuroblastoma cell line	Cell lineSK-N-AS	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTS cell survival assay	In-vitro virus concentration1 MOI	In-vitro result15% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26583803
IDOV_375	Virus nameHerpes simplex virus	Virus strainSeprehvir (HSV1716)	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationΔγ134.5 attenuated virus mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC or from the Pediatric Preclinical Testing Program (PPTP)	Origin of cell lineHuman neuroblastoma cell line	Cell lineSK-N-BE(2)	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTS cell survival assay	In-vitro virus concentration1 MOI	In-vitro result18% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26583803
IDOV_376	Virus nameHerpes simplex virus	Virus strainSeprehvir (HSV1716)	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationΔγ134.5 attenuated virus mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic nude mice (subcutaneously xenografted with CHLA-20)	In-vivo virus concentration1.0E+7 pfu in 100 μL (on days 0, 2 and 4 after the tumor mass reached 150–300 mm³)	In-vivo toxicityNA	In-vivo result42% mice survived	Mode of deliveryIntratumorally	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26583803
IDOV_377	Virus nameHerpes simplex virus	Virus strainSeprehvir (HSV1716)	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationΔγ134.5 attenuated virus mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic nude mice (subcutaneously xenografted with CHP-123)	In-vivo virus concentration1.0E+7 pfu in 100 μL (on days 0, 2 and 4 after the tumor mass reached 150–300 mm³)	In-vivo toxicityNA	In-vivo result63% mice survived	Mode of deliveryIntratumorally	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26583803
IDOV_378	Virus nameHerpes simplex virus	Virus strainSeprehvir (HSV1716)	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationΔγ134.5 attenuated virus mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic nude mice (subcutaneously xenografted with SK-N-AS)	In-vivo virus concentration1.0E+7 pfu in 100 μL (on days 0, 2 and 4 after the tumor mass reached 150–300 mm³)	In-vivo toxicityNA	In-vivo result0% mice survived	Mode of deliveryIntratumorally	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26583803
IDOV_379	Virus nameHerpes simplex virus	Virus strainSeprehvir (HSV1716)	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationΔγ134.5 attenuated virus mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic nude mice (subcutaneously xenografted with SK-N-BE(2))	In-vivo virus concentration1.0E+7 pfu in 100 μL (on days 0, 2 and 4 after the tumor mass reached 150–300 mm³)	In-vivo toxicityNA	In-vivo result18% mice survived	Mode of deliveryIntratumorally	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26583803
IDOV_393	Virus nameHerpes simplex virus	Virus strainICP10PK	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant with R1 domain poorly functional in HSV-1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman malignant melanoma cell lines	Cell lineA2058	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration1 MOI	In-vitro result50% cancer cell death at 48 hours after post infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces JNK/c-Jun, autophagy and pyroptosis activation	Immunogenic effectICP10PK upregulates of caspase-1, -4, and -5, the cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-12, TNF-alpha, lymphotoxina and GM-CSF, and mitogen-activated protein kinases (MAPKs) involved in both PCD and inflammatory processes	Clinical trialNA	PMID26602205
IDOV_394	Virus nameHerpes simplex virus	Virus strainICP10PK	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant with R1 domain poorly functional in HSV-1	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with SP600125 (100 μM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman malignant melanoma cell lines	Cell lineA2058	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration1 MOI	In-vitro result35% cancer cell death at 48 hours after post infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces JNK/c-Jun, autophagy and pyroptosis activation	Immunogenic effectICP10PK upregulates of caspase-1, -4, and -5, the cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-12, TNF-alpha, lymphotoxina and GM-CSF, and mitogen-activated protein kinases (MAPKs) involved in both PCD and inflammatory processes	Clinical trialNA	PMID26602205
IDOV_395	Virus nameHerpes simplex virus	Virus strainICP10PK	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant with R1 domain poorly functional in HSV-1	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with 3-MA (5 mM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman malignant melanoma cell lines	Cell lineA2058	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration1 MOI	In-vitro result38% cancer cell death at 48 hours after post infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces JNK/c-Jun, autophagy and pyroptosis activation	Immunogenic effectICP10PK upregulates of caspase-1, -4, and -5, the cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-12, TNF-alpha, lymphotoxina and GM-CSF, and mitogen-activated protein kinases (MAPKs) involved in both PCD and inflammatory processes	Clinical trialNA	PMID26602205
IDOV_396	Virus nameHerpes simplex virus	Virus strainICP10PK	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant with R1 domain poorly functional in HSV-1	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with z-YVAD- fmk (100 μM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman malignant melanoma cell lines	Cell lineA2058	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration1 MOI	In-vitro result44% cancer cell death at 48 hours after post infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces JNK/c-Jun, autophagy and pyroptosis activation	Immunogenic effectICP10PK upregulates of caspase-1, -4, and -5, the cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-12, TNF-alpha, lymphotoxina and GM-CSF, and mitogen-activated protein kinases (MAPKs) involved in both PCD and inflammatory processes	Clinical trialNA	PMID26602205
IDOV_397	Virus nameHerpes simplex virus	Virus strainICP10PK	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant with R1 domain poorly functional in HSV-1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman malignant melanoma cell lines	Cell lineA375	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration1 MOI	In-vitro result55% cancer cell death at 48 hours after post infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces JNK/c-Jun, autophagy and pyroptosis activation	Immunogenic effectICP10PK upregulates of caspase-1, -4, and -5, the cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-12, TNF-alpha, lymphotoxina and GM-CSF, and mitogen-activated protein kinases (MAPKs) involved in both PCD and inflammatory processes	Clinical trialNA	PMID26602205
IDOV_398	Virus nameHerpes simplex virus	Virus strainICP10PK	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant with R1 domain poorly functional in HSV-1	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with SP600125 (100 μM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman malignant melanoma cell lines	Cell lineA375	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration1 MOI	In-vitro result35% cancer cell death at 48 hours after post infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces JNK/c-Jun, autophagy and pyroptosis activation	Immunogenic effectICP10PK upregulates of caspase-1, -4, and -5, the cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-12, TNF-alpha, lymphotoxina and GM-CSF, and mitogen-activated protein kinases (MAPKs) involved in both PCD and inflammatory processes	Clinical trialNA	PMID26602205
IDOV_399	Virus nameHerpes simplex virus	Virus strainICP10PK	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant with R1 domain poorly functional in HSV-1	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with 3-MA (5 mM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman malignant melanoma cell lines	Cell lineA375	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration1 MOI	In-vitro result44% cancer cell death at 48 hours after post infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces JNK/c-Jun, autophagy and pyroptosis activation	Immunogenic effectICP10PK upregulates of caspase-1, -4, and -5, the cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-12, TNF-alpha, lymphotoxina and GM-CSF, and mitogen-activated protein kinases (MAPKs) involved in both PCD and inflammatory processes	Clinical trialNA	PMID26602205
IDOV_400	Virus nameHerpes simplex virus	Virus strainICP10PK	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant with R1 domain poorly functional in HSV-1	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with z-YVAD- fmk (100 μM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman malignant melanoma cell lines	Cell lineA375	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration1 MOI	In-vitro result42% cancer cell death at 48 hours after post infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces JNK/c-Jun, autophagy and pyroptosis activation	Immunogenic effectICP10PK upregulates of caspase-1, -4, and -5, the cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-12, TNF-alpha, lymphotoxina and GM-CSF, and mitogen-activated protein kinases (MAPKs) involved in both PCD and inflammatory processes	Clinical trialNA	PMID26602205
IDOV_401	Virus nameHerpes simplex virus	Virus strainICP10PK	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant with R1 domain poorly functional in HSV-1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismXenograft male BALB/c nu/nu mice (subcutaneously injected with 1.0E+7 A3755 cells in 100 μl)	In-vivo virus concentration100 μl; 1.0E+6 PFU on day 7	In-vivo toxicityNA	In-vivo resultOn day 29 , tumor growth ratio reached 2 as compared to 13 (tumour growth ratio - dividing each tumour volume measured over time by the initial tumour volume on day 7)	Mode of deliveryIntratumorally	Pathway inducedNA	Immunogenic effectMICA and TNF-alpha expressions are upregulated	Clinical trialNA	PMID26602205
IDOV_832	Virus nameHerpes simplex virus	Virus strainHSV-G207	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant of both copies of gamma 34.5 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNatural	Origin of cell linecolorectal cancer cell line	Cell lineC18	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayBeta galacosidase colorimetric assay	In-vitro virus concentration0.1 MOI	In-vitro result31% cancer cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID10428757
IDOV_833	Virus nameHerpes simplex virus	Virus strainHSV-G207	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant of both copies of gamma 34.5 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNatural	Origin of cell linecolorectal cancer cell line	Cell lineC29	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayBeta galacosidase colorimetric assay	In-vitro virus concentration0.1 MOI	In-vitro result31% cancer cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID10428757
IDOV_834	Virus nameHerpes simplex virus	Virus strainHSV-G207	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant of both copies of gamma 34.5 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNatural	Origin of cell linecolorectal cancer cell line	Cell lineC85	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayBeta galacosidase colorimetric assay	In-vitro virus concentration0.1 MOI	In-vitro result76% cancer cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID10428757
IDOV_835	Virus nameHerpes simplex virus	Virus strainHSV-G207	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant of both copies of gamma 34.5 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNatural	Origin of cell linecolorectal cancer cell line	Cell lineC86	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayBeta galacosidase colorimetric assay	In-vitro virus concentration0.1 MOI	In-vitro result76% cancer cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID10428757
IDOV_836	Virus nameHerpes simplex virus	Virus strainHSV-G207	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant of both copies of gamma 34.5 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNatural	Origin of cell lineCellosaurus cell line	Cell lineHCT-8	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayBeta galacosidase colorimetric assay	In-vitro virus concentration0.1 MOI	In-vitro result76% cancer cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID10428757
IDOV_837	Virus nameHerpes simplex virus	Virus strainHSV-G207	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant of both copies of gamma 34.5 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID10428757
IDOV_838	Virus nameHerpes simplex virus	Virus strainHSV-G207	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant of both copies of gamma 34.5 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic rat xenograft model for C85 cell line	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryDirect injection	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID10428757
IDOV_839	Virus nameHerpes simplex virus	Virus strainHSV-G207	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant of both copies of gamma 34.5 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic rat xenograft model for C86 cell line	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo result4 xenograft model shows partial reduction and 2 shows complete reduction (50% reduction)	Mode of deliveryDirect injection	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID10428757
IDOV_840	Virus nameHerpes simplex virus	Virus strainHSV-G207	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant of both copies of gamma 34.5 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic rat xenograft model for HCT8 cell line	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo result4 xenograft model shows complete reduction and 4 shows partial reduction (complete reduction)	Mode of deliveryDirect injection	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID10428757
IDOV_841	Virus nameHerpes simplex virus	Virus strainHSV-G207	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant of both copies of gamma 34.5 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismMale buffalo rat xenograft model of Morris hepatome McA-RH7777 cell	In-vivo virus concentration1.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor nodes	Mode of deliveryPortal infusion	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID10428757